Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Inotiv (NOTV – Research Report) today. The company’s shares closed yesterday at $5.18.
Hewitt covers the Healthcare sector, focusing on stocks such as Codexis, Apyx Medical, and Inotiv. According to TipRanks, Hewitt has an average return of -0.2% and a 47.86% success rate on recommended stocks.
Currently, the analyst consensus on Inotiv is a Strong Buy with an average price target of $10.17, which is a 96.33% upside from current levels. In a report released on February 8, Jefferies also upgraded the stock to a Buy with a $11.50 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $8.28 and a one-year low of $1.61. Currently, Inotiv has an average volume of 279.1K.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NOTV in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inotiv (NOTV) Company Description:
Bioanalytical Systems, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.
Read More on NOTV:
- Inotiv upgraded to Buy from Hold at Jefferies
- Craig-Hallum remains bullish on Inotiv following solid start to new year
- Inotiv sees FY24 revenue $580M-$590M, consensus $578.14M
- Inotiv reports Q1 EPS (60c), consensus (85c)
- Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update
